Also trades as: 4521.T (JPX) · $vol 3M
KKPCF OTC
Kaken Pharmaceutical Co., Ltd.
1W: +0.0%
1M: -2.4%
3M: -2.4%
YTD: +7.4%
1Y: -7.5%
3Y: -6.0%
5Y: -26.6%
$26.00
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
-$11.1B
-137.4% ▼
Capital Expenditures
$3.0B
+31.4% ▲
5Y CAGR: +5.7%
Free Cash Flow
-$14.2B
-155.8% ▼
Dividends Paid
$6.5B
+9.2% ▲
Buybacks
$2.4B
+60.3% ▲
Net Change in Cash
-$29.7B
-723.0% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $13.9B | $6.8B | $8.0B | $19.4B | $2.2B |
| Depreciation & Amort. | $2.5B | $2.6B | $2.8B | $2.6B | $3.3B |
| Stock-Based Comp. | $0 | $0 | $0 | $0 | $0 |
| Change in Working Capital | -$2.0B | $592M | -$6.4B | $3.0B | -$3.7B |
| Other Non-Cash Items | -$994M | -$724M | -$1.8B | $4.8B | -$12.9B |
| Operating Cash Flow | $13.3B | $9.3B | $2.6B | $29.8B | -$11.1B |
| — Investing Activities — | |||||
| Capital Expenditures | -$3.3B | -$2.2B | -$1.9B | -$4.1B | -$5.5B |
| Acquisitions (Net) | -$5.0B | -$207M | $0 | -$15.4B | $3.2B |
| Investment Purchases | $433M | -$200M | $0 | -$400M | -$201M |
| Investment Sales | $5M | $5M | $516M | $520M | $3.1B |
| Other Investing | -$94M | -$19M | -$4.5B | -$254M | -$337M |
| Investing Cash Flow | -$7.9B | -$2.6B | -$5.9B | -$19.6B | $317M |
| — Financing Activities — | |||||
| Net Debt Issuance | $0 | $0 | $0 | $0 | $0 |
| Stock Repurchased | -$2.4B | -$1.3B | $0 | -$5.9B | -$2.4B |
| Dividends Paid | -$5.7B | -$5.6B | -$5.7B | -$7.2B | -$6.5B |
| Other Financing | -$1M | -$1M | -$1M | $0 | $0 |
| Financing Cash Flow | -$8.1B | -$7.0B | -$5.7B | -$5.4B | -$8.9B |
| Net Change in Cash | -$2.7B | -$365M | -$8.9B | $4.8B | -$29.7B |
| Cash End of Period | $74.6B | $74.3B | $65.3B | $70.1B | $45.0B |
| Free Cash Flow | $10.1B | $7.0B | $410M | $25.4B | -$14.2B |